10 July 2014Americas
Sanofi sues Eli Lilly to halt Lantus biosimilar
French pharmaceutical company Sanofi has sued Eli Lilly for infringing seven patents that cover its blockbuster diabetes drug Lantus (insulin glargine).
Already registered?
Login to your account
If you don't have a login or your access has expired, you will need to purchase a subscription to gain access to this article, including all our online content.
For more information on individual annual subscriptions for full paid access and corporate subscription options please contact us.
To request a FREE 2-week trial subscription, please signup.
NOTE - this can take up to 48hrs to be approved.
For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk
Americas
25 October 2017 Sanofi has taken on Mylan in its latest lawsuit over Lantus (insulin glargine injection), which is used to help control the blood sugar level of those with diabetes.
Editor's picks
Editor's picks
Americas
25 October 2017 Sanofi has taken on Mylan in its latest lawsuit over Lantus (insulin glargine injection), which is used to help control the blood sugar level of those with diabetes.
Americas
25 October 2017 Sanofi has taken on Mylan in its latest lawsuit over Lantus (insulin glargine injection), which is used to help control the blood sugar level of those with diabetes.